Figure 3 | Scientific Reports

Figure 3

From: A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer

Figure 3The alternative text for this image may have been generated using AI.

Enzalutamide response in two patients with BRAF mutant tumors. (A) Computed tomography (CT) imaging for two patients with tumors harboring the BRAF p.K601E mutation prior to starting treatment (left) and 3 months on treatment (right). The yellow arrow indicates a mediastinal lymph node in CRPC-1 and liver metastases in CRPC-2. (B) On-treatment PSA levels for the two patients shown in (A).

Back to article page